<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699086</url>
  </required_header>
  <id_info>
    <org_study_id>Phase II BLI-1008-001</org_study_id>
    <nct_id>NCT02699086</nct_id>
  </id_info>
  <brief_title>A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLite, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLite, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy in adult patients with
      Attention-Deficit Hyperactivity Disorder (ADHD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attention-Deficit Hyperactivity Disorder-Rating Scale-IV (ADHD-RS-IV)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary endpoint is the change of ADHD Rating Scale-IV (ADHD-RS-IV) total score from baseline to Week 8 compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conners' Adult Attention- Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S) 18-Item total ADHD symptom score up to 8 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-ADHD- Severity (CGI-ADHD-S) and Clinical Global Impression-ADHD- improvement (CGI-ADHD-I)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical Global Impression-ADHD- Severity (CGI-ADHD-S) and Clinical Global Impression-ADHD- improvement (CGI-ADHD-I) score of 2 or lower.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CANTAB</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference from baseline to after drug administration in the three CANTAB scores were considered.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Attention-Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>2 PDC-1421 Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 PDC-1421 Capsule trice daily, p.o. after meal for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 PDC-1421 Capsule plus 1 placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 PDC-1421 Capsule plus 1 placebo trice daily, p.o. after meal for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo trice daily, p.o. after meal for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDC-1421 Capsule</intervention_name>
    <arm_group_label>2 PDC-1421 Capsule</arm_group_label>
    <arm_group_label>1 PDC-1421 Capsule plus 1 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>1 PDC-1421 Capsule plus 1 placebo</arm_group_label>
    <arm_group_label>2 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-65 years

          2. Female subjects of child-bearing potential must test negative to pregnancy and use
             appropriate birth control method from the beginning of study to the 15 days later
             after ending of study

          3. Subjects must be able to understand and willing to sign informed consent

          4. are able to discontinue the use of any psychotropic medications for the treatment of
             ADHD symptoms at screening

          5. meet strict operational criteria for adult ADHD according to the Diagnostic and
             Statistical Manual of Mental Disorders, 5th Edition (DSM-5)

          6. a total score of 20 or higher on the 18-item total ADHD symptoms score of

             Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report:

             Short Version (CAARS-S:S) at screening

          7. have a moderate or severe symptom of ADHD with score of 4 or higher in Clinical Global
             Impression-ADHD-Severity (CGI-ADHD-S) at screening

        Exclusion Criteria:

          1. have any clinically significant concurrent medical condition (endocrine, renal,
             respiratory, cardiovascular, hematological, immunological, cerebrovascular,
             neurological, anorexia, obesity or malignancy) that has become unstable and may
             interfere with the interpretation of safety and efficacy evaluations

          2. have any clinically significant abnormal laboratory, vital sign, physical examination,
             or electrocardiogram (ECG) findings at screening that, in the opinion of the
             investigator, may interfere with the interpretation of safety or efficacy evaluations

          3. have known serological evidence of human immunodeficiency virus (HIV) antibody

          4. are pregnant as confirmed by a positive pregnancy test at screening

          5. have corrected QT Interval (QTc) values &gt;450 msec at screening using Fridericia's QTc
             formula

          6. have current of bipolar and psychotic disorders

          7. have a current major depression disorder, obsessive-compulsive disorder, post-
             traumatic stress disorder, generalized anxiety disorder, panic disorder and eating
             disorder (also if treated but not currently symptomatic)

          8. have any history of a significant suicide attempt, or possess a current risk of
             attempting suicide, in the investigator's opinion, based on clinical interview and
             responses provided on the Beck Scale for Suicidal Ideation (BSS)

          9. have a history of jailing or imprisonment in the past 6 months due to worsening of
             symptoms of ADHD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frank Chang, PhD</last_name>
    <phone>886-3-657-9631</phone>
    <phone_ext>13</phone_ext>
    <email>frankchang@bioliteinc.com</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

